All In Biotech

Drug Trial Radar · NCT02339155

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)

Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 573 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

573

Actual

Start

Feb 24, 2015

Primary completion

Jan 3, 2017

Study completion Jun 6, 2017

Sponsor

Lead sponsor
Emergent BioSolutionsIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jan 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1.

Conditions

  • Infections, Bacterial

Interventions

  • AVABiological

    Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration

  • RaxibacumabBiological

    Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration

  • DiphenhydramineDrug

    Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose), Between the AVA Alone and the AVA With Raxibacumab Treatment GroupsTime frame: Day 29

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Edgewater, Florida

  • GSK Investigational Site

    Overland Park, Kansas

  • GSK Investigational Site

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.